Indeed, clinical evidence has revealed that elevated levels of tissue or plasma CCL5 are markers of an unfavourable outcome in patients with either melanoma, breast, cervical, prostate, gastric or pancreatic cancer [13]–[20]. This evidence concerns the gene CCL5 and pancreatic neoplasm.